Do analysts rate EXOZ or LEXX?

Lexaria Bioscience has a consensus price target of $1.50, indicating a potential upside of 158.18%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is EXOZ or LEXX more profitable?

Lexaria Bioscience's return on equity of -174.93% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Lexaria Bioscience N/A -174.93% -143.89%

Is CNTX or LEXX more profitable?

Context Therapeutics' return on equity of -59.95% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -59.95% -54.78% Lexaria Bioscience N/A -174.93% -143.89%

Is FLNA or LEXX more profitable?

Cassava Sciences' return on equity of -53.90% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -53.90% -34.20% Lexaria Bioscience N/A -174.93% -143.89%

Is INKT or LEXX more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -118.57% Lexaria Bioscience N/A -174.93% -143.89%

Do analysts prefer LEXX or BYSI?

Lexaria Bioscience presently has a consensus price target of $1.50, indicating a potential upside of 158.18%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, equities analysts clearly believe Lexaria Bioscience is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LEXX or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -174.93% -143.89% BeyondSpring N/A N/A -14.00%

Lexaria Bioscience (LEXX) Competitors

$0.58 -0.02 (-3.17%)

As of 10:37 AM Eastern

Compare

LEXX vs. EXOZ, CNTX, FLNA, INKT, and BYSI

Should you buy Lexaria Bioscience stock or one of its competitors? MarketBeat compares Lexaria Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lexaria Bioscience include eXoZymes (EXOZ), Context Therapeutics (CNTX), Cassava Sciences (FLNA), MiNK Therapeutics (INKT), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry.

How does Lexaria Bioscience compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

eXoZymes has a beta of 2.73, meaning that its share price is 173% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

In the previous week, eXoZymes had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 1 mentions for eXoZymes and 0 mentions for Lexaria Bioscience. eXoZymes' average media sentiment score of 0.00 beat Lexaria Bioscience's score of -3.00 indicating that eXoZymes is being referred to more favorably in the media.

Company	Overall Sentiment
eXoZymes	Neutral
Lexaria Bioscience	Very Negative

13.1% of Lexaria Bioscience shares are held by institutional investors. 72.4% of eXoZymes shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Lexaria Bioscience has a consensus price target of $1.50, indicating a potential upside of 158.18%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

eXoZymes has higher earnings, but lower revenue than Lexaria Bioscience. eXoZymes is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	746.27	-$9.16M	-$1.14	N/A
Lexaria Bioscience	$710K	20.29	-$11.90M	-$0.34	N/A

Lexaria Bioscience's return on equity of -174.93% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Lexaria Bioscience	N/A	-174.93%	-143.89%

Summary

Lexaria Bioscience beats eXoZymes on 8 of the 15 factors compared between the two stocks.

How does Lexaria Bioscience compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

In the previous week, Context Therapeutics had 3 more articles in the media than Lexaria Bioscience. MarketBeat recorded 3 mentions for Context Therapeutics and 0 mentions for Lexaria Bioscience. Context Therapeutics' average media sentiment score of 1.27 beat Lexaria Bioscience's score of -3.00 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Context Therapeutics	Positive
Lexaria Bioscience	Very Negative

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Context Therapeutics currently has a consensus target price of $6.17, suggesting a potential upside of 899.46%. Lexaria Bioscience has a consensus target price of $1.50, suggesting a potential upside of 158.18%. Given Context Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Context Therapeutics is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Context Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Context Therapeutics' return on equity of -59.95% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Lexaria Bioscience	N/A	-174.93%	-143.89%

Lexaria Bioscience has higher revenue and earnings than Context Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Lexaria Bioscience	$710K	20.29	-$11.90M	-$0.34	N/A

Summary

Context Therapeutics beats Lexaria Bioscience on 11 of the 15 factors compared between the two stocks.

How does Lexaria Bioscience compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Cassava Sciences has a beta of -0.73, indicating that its share price is 173% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Cassava Sciences' return on equity of -53.90% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Lexaria Bioscience	N/A	-174.93%	-143.89%

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cassava Sciences currently has a consensus target price of $5.00, suggesting a potential upside of 386.19%. Lexaria Bioscience has a consensus target price of $1.50, suggesting a potential upside of 158.18%. Given Cassava Sciences' higher probable upside, equities analysts clearly believe Cassava Sciences is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cassava Sciences had 2 more articles in the media than Lexaria Bioscience. MarketBeat recorded 2 mentions for Cassava Sciences and 0 mentions for Lexaria Bioscience. Cassava Sciences' average media sentiment score of 0.00 beat Lexaria Bioscience's score of -3.00 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cassava Sciences	Neutral
Lexaria Bioscience	Very Negative

Lexaria Bioscience has higher revenue and earnings than Cassava Sciences. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Lexaria Bioscience	$710K	20.29	-$11.90M	-$0.34	N/A

Summary

Cassava Sciences beats Lexaria Bioscience on 7 of the 12 factors compared between the two stocks.

How does Lexaria Bioscience compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

In the previous week, MiNK Therapeutics had 2 more articles in the media than Lexaria Bioscience. MarketBeat recorded 2 mentions for MiNK Therapeutics and 0 mentions for Lexaria Bioscience. MiNK Therapeutics' average media sentiment score of 1.20 beat Lexaria Bioscience's score of -3.00 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MiNK Therapeutics	Positive
Lexaria Bioscience	Very Negative

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MiNK Therapeutics' return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Lexaria Bioscience	N/A	-174.93%	-143.89%

MiNK Therapeutics presently has a consensus price target of $35.00, suggesting a potential upside of 215.71%. Lexaria Bioscience has a consensus price target of $1.50, suggesting a potential upside of 158.18%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe MiNK Therapeutics is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lexaria Bioscience has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Lexaria Bioscience	$710K	20.29	-$11.90M	-$0.34	N/A

MiNK Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Summary

MiNK Therapeutics beats Lexaria Bioscience on 9 of the 14 factors compared between the two stocks.

How does Lexaria Bioscience compare to BeyondSpring?

Lexaria Bioscience (NASDAQ:LEXX) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

BeyondSpring has higher revenue and earnings than Lexaria Bioscience. BeyondSpring is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	20.29	-$11.90M	-$0.34	N/A
BeyondSpring	$1.75M	30.10	-$1.01M	-$0.14	N/A

In the previous week, BeyondSpring's average media sentiment score of 0.00 beat Lexaria Bioscience's score of -3.00 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Lexaria Bioscience	Very Negative
BeyondSpring	Neutral

13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lexaria Bioscience presently has a consensus price target of $1.50, indicating a potential upside of 158.18%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, equities analysts clearly believe Lexaria Bioscience is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lexaria Bioscience has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market.

BeyondSpring's return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
BeyondSpring	N/A	N/A	-14.00%

Summary

BeyondSpring beats Lexaria Bioscience on 10 of the 14 factors compared between the two stocks.

Get Lexaria Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEXX vs. The Competition

Export

Metric	Lexaria Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.40M	$3.64B	$6.80B	$12.37B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-1.71	20.71	27.09	24.07
Price / Sales	20.29	302.58	520.26	91.86
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	4.47	7.99	10.64	6.20
Net Income	-$11.90M	$23.81M	$3.60B	$331.63M
7 Day Performance	-1.06%	-1.92%	-1.41%	-1.54%
1 Month Performance	7.55%	1.88%	0.97%	-1.17%
1 Year Performance	-39.14%	43.58%	24.23%	17.81%

Lexaria Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LEXX Lexaria Bioscience	1.4589 of 5 stars	$0.58 -3.2%	$1.50 +158.2%	-36.5%	$14.40M	$710K	N/A	7	Gap Up
EXOZ eXoZymes	0.1244 of 5 stars	$7.00 +9.9%	N/A	-39.5%	$58.67M	$70K	N/A	29	Gap Up
CNTX Context Therapeutics	3.2198 of 5 stars	$0.62 -0.1%	$6.17 +890.0%	-30.8%	$57.31M	N/A	N/A	7	News Coverage Positive News Analyst Downgrade
FLNA Cassava Sciences	1.4628 of 5 stars	$1.09 -5.2%	$5.00 +358.7%	-53.8%	$55.55M	N/A	N/A	20	News Coverage
INKT MiNK Therapeutics	3.0637 of 5 stars	$11.41 +2.3%	$35.00 +206.7%	-47.0%	$55.55M	N/A	N/A	30	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEXX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexaria Bioscience (LEXX) Competitors

LEXX vs. EXOZ, CNTX, FLNA, INKT, and BYSI

How does Lexaria Bioscience compare to eXoZymes?

Summary

How does Lexaria Bioscience compare to Context Therapeutics?

Summary

How does Lexaria Bioscience compare to Cassava Sciences?

Summary

How does Lexaria Bioscience compare to MiNK Therapeutics?

Summary

How does Lexaria Bioscience compare to BeyondSpring?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX vs. The Competition

Lexaria Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexaria Bioscience (LEXX) Competitors

LEXX vs. EXOZ, CNTX, FLNA, INKT, and BYSI

How does Lexaria Bioscience compare to eXoZymes?

Which has more risk and volatility, EXOZ or LEXX?

Does the media prefer EXOZ or LEXX?

Do insiders and institutionals have more ownership in EXOZ or LEXX?

Do analysts rate EXOZ or LEXX?

Which has stronger earnings & valuation, EXOZ or LEXX?

Is EXOZ or LEXX more profitable?

Summary

How does Lexaria Bioscience compare to Context Therapeutics?

Does the media prefer CNTX or LEXX?

Do institutionals and insiders hold more shares of CNTX or LEXX?

Do analysts rate CNTX or LEXX?

Which has more risk & volatility, CNTX or LEXX?

Is CNTX or LEXX more profitable?

Which has better earnings & valuation, CNTX or LEXX?

Summary

How does Lexaria Bioscience compare to Cassava Sciences?

Which has more risk & volatility, FLNA or LEXX?

Is FLNA or LEXX more profitable?

Do institutionals & insiders hold more shares of FLNA or LEXX?

Do analysts prefer FLNA or LEXX?

Does the media refer more to FLNA or LEXX?

Which has higher earnings and valuation, FLNA or LEXX?

Summary

How does Lexaria Bioscience compare to MiNK Therapeutics?

Does the media prefer INKT or LEXX?

Do insiders & institutionals hold more shares of INKT or LEXX?

Is INKT or LEXX more profitable?

Do analysts prefer INKT or LEXX?

Which has preferable valuation and earnings, INKT or LEXX?

Which has more volatility & risk, INKT or LEXX?

Summary

How does Lexaria Bioscience compare to BeyondSpring?

Which has preferable earnings and valuation, LEXX or BYSI?

Does the media refer more to LEXX or BYSI?

Do institutionals & insiders believe in LEXX or BYSI?

Do analysts prefer LEXX or BYSI?

Which has more risk & volatility, LEXX or BYSI?

Is LEXX or BYSI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX vs. The Competition

Lexaria Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools